Is cardiac resynchronization therapy (CRT) indicated in a patient with chronic persistent atrial fibrillation and heart failure with reduced ejection fraction?

CRT is Indicated in Chronic Persistent Atrial Fibrillation with HFrEF, But Requires Aggressive Rate Control or AV Node Ablation

CRT should be offered to patients with chronic persistent atrial fibrillation and HFrEF who meet standard CRT criteria (LVEF ≤35%, QRS ≥120ms, NYHA class II-IV on optimal GDMT), with the critical requirement of achieving >90-95% biventricular pacing through either aggressive medical rate control or AV node ablation. 1

The Evidence Framework

The 2022 AHA/ACC/HFSA guidelines establish CRT indications primarily based on trials conducted in sinus rhythm patients, but the algorithm explicitly addresses AF as a "special circumstance" requiring consideration 1. The European position statement emphasizes that CRT remains underutilized, with only one in three eligible patients receiving devices 2.

The Atrial Fibrillation Challenge

The core issue: AF significantly compromises CRT efficacy compared to sinus rhythm. Meta-analysis of 83,571 patients demonstrates that CRT-AF patients have 47% higher all-cause mortality and 86% higher cardiovascular mortality than CRT-NSR patients 3. The mechanism is straightforward—irregular ventricular activation and inadequate biventricular pacing percentage undermine the resynchronization benefit.

The Critical Decision Point: Ensuring Adequate Biventricular Pacing

Option 1: Aggressive Medical Rate Control

• Target resting heart rate <90 bpm
• Requires documented ≥90-95% biventricular pacing on 24-hour Holter monitoring (device counters are less accurate) 4
• Studies show this approach can achieve similar outcomes to sinus rhythm patients when pacing percentage is adequate 4
• Pitfall: Many patients fail to achieve adequate biventricular pacing with medical therapy alone

Option 2: AV Node Ablation (Preferred When Medical Control Inadequate)

• Meta-analysis shows AV node ablation reduces all-cause mortality by 52% in CRT-AF patients (OR: 0.485) 3
• With ablation, mortality differences between AF and sinus rhythm patients disappear (OR: 1.245, p=0.165) 3
• Guarantees 100% biventricular pacing

However, the 2026 CAAN-AF trial contradicts this: This randomized trial of 143 patients found no difference in the composite endpoint of mortality and HF events between AV node ablation versus medical rate control (IRR 1.16,95% CI 0.60-2.24) 5. This is the highest quality evidence available—a recent RCT—but was terminated early for futility with small sample size, limiting its generalizability.

Reconciling Contradictory Evidence

The discrepancy between observational data strongly favoring AV node ablation 3 and the neutral CAAN-AF trial 5 likely reflects:

• CAAN-AF's early termination and underpowering
• Improved medical rate control strategies in the modern era
• Better device optimization protocols in both arms of CAAN-AF

Clinical approach: Start with aggressive medical rate control. If 24-hour Holter monitoring shows <90% biventricular pacing despite optimal medical therapy, proceed with AV node ablation 4.

Practical Implementation Algorithm

1. Confirm standard CRT criteria: LVEF ≤35%, QRS ≥120ms (preferably LBBB ≥150ms), NYHA II-IV, on GDMT >3 months 1

2. Optimize rate control medications targeting HR <90 bpm

3. Implant CRT device with optimization

4. Obtain 24-hour Holter at 1-3 months post-implant (not just device interrogation)

5. If biventricular pacing <90%: Proceed with AV node ablation 3, 4

6. If biventricular pacing ≥90%: Continue medical management with regular monitoring

Expected Outcomes

When adequate biventricular pacing is achieved (whether through medical therapy or ablation):

• Clinical response rates similar to sinus rhythm patients 6
• Functional improvements may actually be greater in AF patients (71% vs 39% functional responders) 6
• LVEF improvements of 6-7% 4
• NYHA class improvement from III to II 4
• 6-minute walk distance increases of ~105 meters 4

Critical Caveats

• Non-ischemic cardiomyopathy responds better than ischemic etiology 7
• Device optimization is mandatory in all AF patients 5
• The term "non-responder" is misleading—CRT provides disease modification across a spectrum, not binary response 2
• Consider AF ablation in appropriate candidates, as 72% of HFrEF patients achieve LVEF >35% post-ablation, potentially affecting CRT indication 7